Adverse Drug Reaction Monitoring Centre, NIPER Hajipur

1. About Pharmacovigilance Programme of India (PvPI)

The Pharmacovigilance Programme of India (PvPI) is an initiative of the Ministry of Health & Family Welfare, Government of India, coordinated by the Indian Pharmacopoeia Commission (IPC), Ghaziabad. The programme aims to ensure the safe and rational use of medicines by monitoring, assessing, and preventing adverse drug reactions (ADRs). It encourages spontaneous reporting of ADRs by healthcare professionals and patients, thereby strengthening the national pharmacovigilance system and enhancing patient safety.

2.NIPER Hajipur under PvPI

NIPER Hajipur has been functioning as an Adverse Drug Reaction Monitoring Centre (AMC) under the Pharmacovigilance Programme of India (PvPI) since December 2021. The Centre is actively engaged in the collection, assessment, and reporting of Individual Case Safety Reports (ICSRs) to the National Coordination Centre (NCC), Indian Pharmacopoeia Commission. Since its inception, the Centre has submitted a cumulative total of 6,479 ICSRs (up to June 2026), contributing significantly to the national pharmacovigilance database. The Centre continues to promote pharmacovigilance practices and supports medicine safety surveillance through continuous ADR monitoring and reporting.

3.Activities & Highlights

5th National Pharmacovigilance Week – 2025

The 5th National Pharmacovigilance Week was celebrated on 18 September 2025 with the objective of promoting medicine safety and strengthening pharmacovigilance practices. The programme featured expert sessions by eminent speakers from academia, regulatory authorities, and the pharmaceutical industry, covering real-world pharmacovigilance, regulatory requirements, and global drug safety practices. It provided an interactive platform for participants to enhance their understanding of Adverse Drug Reaction (ADR) reporting, pharmacovigilance systems, and their role in improving patient safety